KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

TherapeuticsMD (TXMD) Depreciation & Amortization - Total (2018 - 2023)

TherapeuticsMD filings provide 7 years of Depreciation & Amortization - Total readings, the most recent being $100000.0 for Q4 2023.

  • On a quarterly basis, Depreciation & Amortization - Total fell 50.0% to $100000.0 in Q4 2023 year-over-year; TTM through Sep 2024 was $100000.0, a 71.99% decrease, with the full-year FY2023 number at $100000.0, down 83.33% from a year prior.
  • Depreciation & Amortization - Total hit $100000.0 in Q4 2023 for TherapeuticsMD, down from $130000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization - Total ranged from a high of $329000.0 in Q1 2022 to a low of $27000.0 in Q1 2023.
  • Median Depreciation & Amortization - Total over the past 3 years was $165000.0 (2022), compared with a mean of $166819.5.
  • Biggest five-year swings in Depreciation & Amortization - Total: skyrocketed 63.22% in 2019 and later plummeted 91.79% in 2023.
  • TherapeuticsMD's Depreciation & Amortization - Total stood at $66556.0 in 2019, then surged by 200.5% to $200000.0 in 2022, then crashed by 50.0% to $100000.0 in 2023.
  • The last three reported values for Depreciation & Amortization - Total were $100000.0 (Q4 2023), $130000.0 (Q3 2023), and $27000.0 (Q1 2023) per Business Quant data.